Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$-13 Mln
ROE
-6.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
6.3
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
5,071,935
CFO
$-201.58 Mln
EBITDA
$-243.23 Mln
Net Profit
$-297.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
| -- | -- | -- | -- | -61.8 | -74.7 | -51.9 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
| -34.1 | -93.6 | -82.3 | -45.9 | -38.7 | 49.8 | 185.3 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eloxx Pharmaceuticals (ELOX)
|
0.1 | 1.0 | 0.0 | -6.0 | -- | 33.1 | -- | 6.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel,... and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. is based in Arlington, Massachusetts. Read more
President, CEO & Director
Mr. Sumit Aggarwal M.B.A.
President, CEO & Director
Mr. Sumit Aggarwal M.B.A.
Headquarters
Arlington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Eloxx Pharmaceuticals Inc (ELOX) is $0.13 (NASDAQ) as of 02-Apr-2026 12:00 EDT. Eloxx Pharmaceuticals Inc (ELOX) has given a return of -61.79% in the last 3 years.
Since, TTM earnings of Eloxx Pharmaceuticals Inc (ELOX) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
-0.16
|
-0.15
|
|
2022
|
-0.11
|
-0.37
|
|
2021
|
-0.02
|
0.07
|
The 52-week high and low of Eloxx Pharmaceuticals Inc (ELOX) are Rs 0.14 and Rs 0.13 as of 05-Apr-2026.
Eloxx Pharmaceuticals Inc (ELOX) has a market capitalisation of $ 1 Mln as on 27-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Eloxx Pharmaceuticals Inc (ELOX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.83
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.